IP Verse

Use Of Trl Agonist And Anti-Cd47 Agent To Enhance Phagocytosis Of Cancer Cells

Patent No. EP3656443 (titled "Use Of Trl Agonist And Anti-Cd47 Agent To Enhance Phagocytosis Of Cancer Cells") was filed by The Board OF Trustees OF The Leland Stanford Junior University on Jan 21, 2016. The application was issued on Sep 29, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENMABJun 29, 2022J A KEMP
PFIZERJun 29, 2022PFIZER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3656443

THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Application Number
EP19197485A
Filing Date
Jan 21, 2016
Status
Granted And Under Opposition
Aug 27, 2021
Publication Date
Sep 29, 2021
External Links
Slate, EP3656443B1, Google Patents